Yan-Ge Wei1, Dong-Bin Cai2, Juan Liu3, Rong-Xun Liu1, Shi-Bin Wang4, Yan-Qing Tang5, Wei Zheng6, Fei Wang7. 1. Henan Key Laboratory of Immunology and Targeted Drug, Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang 453003, Henan, PR China; Department of Psychiatry, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, PR China; Brain Function Research Section, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, PR China. 2. Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518000, Guangdong, PR China. 3. Department of Psychiatry, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, PR China; Brain Function Research Section, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, PR China. 4. Guangdong Mental Health Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510370, Guangdong, PR China. 5. Department of Psychiatry, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, PR China; Brain Function Research Section, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, PR China; Department of Geriatrics, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, PR China. 6. Department of Psychiatry, the Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou 510370, Guangdong, PR China. 7. Department of Psychiatry, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, PR China; Brain Function Research Section, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, PR China; Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, USA. Electronic address: fei.wang@yale.edu.
Abstract
BACKGROUND: Lipid profile disturbances are frequently observed in major depressive disorder (MDD) and constitute to high mortality rates. However, less is known about whether this risk is present in patients with first-episode MDD. Therefore, this meta-analysis was conducted to examine if lipid parameters differed between healthy controls and first-episode MDD patients. METHODS: Cochrane Library, PubMed, PsycINFO, EMBASE, Chinese Journal Net, and WanFang databases were searched from inception to October 23, 2018. The primary outcomes were triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and total cholesterol levels. RESULTS: A total of 11 case-control studies compared 690 subjects with first-episode MDD and 614 healthy controls were included and analyzed. Compared to healthy controls, patients with first-episode MDD were significantly associated with higher triglyceride (SMD = 0.29, 95% CI: 0.09, 0.48, P = 0.004) and lower HDL cholesterol levels (SMD = -0.54, 95% CI: -0.86, -0.22, P = 0.001). Subgroup analyses revealed that first-episode MDD patients with higher triglyceride and lower HDL levels were found only in Chinese and plasma group when compared to healthy controls (P < 0.05). Meta-regression analysis showed that the significant heterogeneity for triglyceride and HDL cholesterol was partly explained by the quality of study. No significant difference was found in LDL cholesterol and total cholesterol levels between the two groups. LIMITATIONS: Heterogeneity was relatively high among the included studies. CONCLUSIONS: Elevated triglyceride and decreased HDL cholesterol levels may be associated with first-episode MDD. Findings support early lipid monitoring and interventions targeting healthy lifestyle.
BACKGROUND: Lipid profile disturbances are frequently observed in major depressive disorder (MDD) and constitute to high mortality rates. However, less is known about whether this risk is present in patients with first-episode MDD. Therefore, this meta-analysis was conducted to examine if lipid parameters differed between healthy controls and first-episode MDD patients. METHODS: Cochrane Library, PubMed, PsycINFO, EMBASE, Chinese Journal Net, and WanFang databases were searched from inception to October 23, 2018. The primary outcomes were triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and total cholesterol levels. RESULTS: A total of 11 case-control studies compared 690 subjects with first-episode MDD and 614 healthy controls were included and analyzed. Compared to healthy controls, patients with first-episode MDD were significantly associated with higher triglyceride (SMD = 0.29, 95% CI: 0.09, 0.48, P = 0.004) and lower HDL cholesterol levels (SMD = -0.54, 95% CI: -0.86, -0.22, P = 0.001). Subgroup analyses revealed that first-episode MDD patients with higher triglyceride and lower HDL levels were found only in Chinese and plasma group when compared to healthy controls (P < 0.05). Meta-regression analysis showed that the significant heterogeneity for triglyceride and HDL cholesterol was partly explained by the quality of study. No significant difference was found in LDL cholesterol and total cholesterol levels between the two groups. LIMITATIONS: Heterogeneity was relatively high among the included studies. CONCLUSIONS: Elevated triglyceride and decreased HDL cholesterol levels may be associated with first-episode MDD. Findings support early lipid monitoring and interventions targeting healthy lifestyle.
Authors: Farah Qureshi; Jackie Soo; Ying Chen; Brita Roy; Donald M Lloyd-Jones; Laura D Kubzansky; Julia K Boehm Journal: Am J Prev Med Date: 2022-01-20 Impact factor: 5.043